Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine

The FLAIR study demonstrated noninferiority of monthly long-acting cabotegravir + rilpivirine versus daily oral dolutegravir/abacavir/lamivudine for maintaining virologic suppression. Three participants who received long-acting therapy had confirmed virologic failure (CVF) at Week 48, and all had HI...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeffrey, Jerry L., St. Clair, Marty, Wang, Ping, Wang, Chunfu, Li, Zhufang, Beloor, Jagadish, Talarico, Christine, Fridell, Robert, Krystal, Mark, White, C. Thomas, Griffith, Sandy, D’Amico, Ronald, Smith, Kimberly, Van Eygen, Veerle, Vingerhoets, Johan, Vandermeulen, Kati, Spreen, William, van Lunzen, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923183/
https://www.ncbi.nlm.nih.gov/pubmed/34978890
http://dx.doi.org/10.1128/aac.01702-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923183/
https://www.ncbi.nlm.nih.gov/pubmed/34978890
http://dx.doi.org/10.1128/aac.01702-21

Ejemplares similares